NAPA, Calif., Jan. 9 /PRNewswire/ -- Dey, L.P. today announced that it has settled a lawsuit brought against it and other companies by the State of Alabama in January 2005 pertaining to Medicaid reimbursements paid by the state to pharmacists and other healthcare providers. In exchange for a full release of claims, Dey has agreed to pay the state $4.75 million, $750,000 of which accounts for outside legal fees and expenses.
As part of the acquisition agreement between Mylan Inc. (Dey’s parent company) and Merck KGaA (Dey’s former parent company), Merck has agreed to indemnify Mylan in connection with this settlement and for all liability for all pending and future related Medicaid reimbursement lawsuits involving Dey.
As part of the settlement, the state acknowledges that the settlement does not constitute admission or evidence of fault, liability or unlawful conduct by Dey.
About Dey, L.P.
Dey, L.P., a subsidiary of Mylan Inc. , is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey, L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey, L.P. include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.cyanokit.com, www.duoneb.com, www.epipen.com and www.perforomist.com.
About Mylan Inc.
Mylan Inc. is one of the world’s leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry’s broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan’s fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.
hullman@fkhealth.com
CONTACT: Dey, L.P. Media Line, +1-800-755-5560 x8363; or Harriet Ullman of
Feinstein Kean Healthcare for Dey, L.P., +1-617-761-6776,
hullman@fkhealth.com
Web site: http://www.dey.com/
http://www.accuneb.com/
http://www.curosurfusa.com/
http://www.cyanokit.com/
http://www.duoneb.com/
http://www.epipen.com/
http://www.perforomist.com/
